DDInter373 DDInter1082
Chromic chloride, for injection, is a sterile, nonpyrogenic solution intended for use as an additive to solutions for Total Parenteral Nutrition (TPN).
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Chromic chloride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Miglitol
Chromic chloride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Chromic chloride may cause a moderate interaction that could exacerbate diseases when taken with Miglitol
Chromic chloride may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide